GF73133748
Platinum
wire reel, 2m, diameter 0.05mm, hard, 99.99%
Sinónimos:
Platinum, PT005115
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Fórmula empírica (notación de Hill):
Pt
Número de CAS:
Peso molecular:
195.08
MDL number:
UNSPSC Code:
12141734
PubChem Substance ID:
NACRES:
NA.23
assay
99.99%
form
wire
manufacturer/tradename
Goodfellow 731-337-48
resistivity
10.6 μΩ-cm, 20°C
L × diam.
2 m × 0.05 mm
bp
3827 °C (lit.)
mp
1772 °C (lit.)
density
21.45 g/cm3 (lit.)
SMILES string
[Pt]
InChI
1S/Pt
InChI key
BASFCYQUMIYNBI-UHFFFAOYSA-N
Categorías relacionadas
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Storage Class
13 - Non Combustible Solids
wgk_germany
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Antonio González
Future oncology (London, England), 9(12 Suppl), 29-35 (2013-11-15)
Ovarian carcinoma is still one of the most common causes of death from cancer in the western world. Despite high sensitivity to chemotherapy, the majority of patients will relapse within 3 years. In this article the focus is centered on
Nicoletta Colombo
Future oncology (London, England), 9(12 Suppl), 19-23 (2013-11-15)
Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.
Himashinie V K Diyabalanage et al.
Cancer letters, 329(1), 1-8 (2012-10-04)
One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has
Hai-Bo Wei et al.
Chinese medical journal, 125(16), 2902-2907 (2012-08-31)
Platinum-based regimens are used as standard first-line chemotherapy in non-small cell lung cancer (NSCLC) patients. To study if pharmacogenetic approach may allow a tailored selection of platinum chemotherapy for advanced NSCLC, we performed a meta-analysis to compare chemosensitivity to platinum
A G Quiroga
Journal of inorganic biochemistry, 114, 106-112 (2012-07-24)
This focused review is devoted to our advances in developing trans platinum complexes as antitumoral complexes, in particular those bearing aliphatic amines. It includes some fundamental aspects of the understanding of non conventional metallodrug mechanism. The perspective is arranged by
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico